Biocardia Stock Plunges 12.76% Amid Market Volatility

On August 5, 2025, Biocardia's stock experienced a significant drop of 12.76% in pre-market trading, reflecting investor concerns and market volatility.

Artelo Biosciences, Inc. recently entered into a Securities Purchase Agreement with accredited investors, raising approximately $9.475 million through the sale of common stock and warrants. The proceeds from this offering will be used to purchase the digital currency SOL, with any remaining funds allocated to general corporate and working capital purposes. This strategic move by Artelo Biosciences highlights the company's shift towards digital asset investments, which could potentially impact Biocardia's stock performance as investors reassess the risks and opportunities associated with such investments.

Additionally, Artelo Biosciences received favorable guidance from the UK MHRA for a first-in-human Phase 1 clinical trial of ART12.11, a proprietary CBD:TMP cocrystal being developed for the treatment of anxiety and depression. This positive regulatory development could bolster investor confidence in the biopharmaceutical sector, potentially mitigating some of the negative sentiment surrounding Biocardia's stock drop.